Telix Pharmaceuticals Ltd has released a press release.
APAC Regulatory Progress Prostate and Kidney Cancer Imaging
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Appendix 4C and Activities Report for June 2022 Quarter
- Kevin Richardson appointed as CEO, Telix Americas
- Zircon Kidney Cancer Imaging Study completes Enrollment
- Distribution Agreement with Isologic for Illuccix in Canada
- Expansion of Partnership with RefleXion for Prostate Cancer
Later from Telix Pharmaceuticals
- Grand Pharmaceutical Groups investment in Telix
- Appendix 4D - Results for announcement to the market
- 1H 2022 - Results Presentation
- Final IPAX-1 Study Data Confirms Safety Tolerability Profile
- Telix Withdraws Marketing Application for Illuccix in Europe
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals